Calcitriol - Generic Drug Details

What are the generic drug sources for calcitriol and what is the scope of freedom to operate?

Calcitriol is the generic ingredient in four branded drugs marketed by Amneal Pharms, Bionpharma, Hikma, Onesource Specialty, Sun Pharm, Teva, Esjay Pharma, Abbvie, Am Regent, Fresenius Kabi Usa, Fresenius Medcl, Gland, Hospira, Long Grove Pharms, Rockwell Medcl, Sagent Pharms, Teva Parenteral, Galderma Labs Lp, Anda Repository, and Rising, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for calcitriol. Twenty-two suppliers are listed for this compound.

Summary for calcitriol

US Patents:	0
Tradenames:	4
Applicants:	20
NDAs:	22
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	181
Patent Applications:	6,645
Drug Prices:	Drug price trends for calcitriol
Drug Sales Revenues:	Drug sales revenues for calcitriol
What excipients (inactive ingredients) are in calcitriol?	calcitriol excipients list
DailyMed Link:	calcitriol at DailyMed

See drug prices for calcitriol

See drug sales revenues for calcitriol

Recent Clinical Trials for calcitriol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	NA
Al-Azhar University	NA
University of Split, School of Medicine	NA

See all calcitriol clinical trials

Pharmacology for calcitriol

Drug Class

Vitamin D3 Analog

Medical Subject Heading (MeSH) Categories for calcitriol

Bone Density Conservation Agents

Calcium Channel Agonists

Vitamins

Anatomical Therapeutic Chemical (ATC) Classes for calcitriol

A11CC	Vitamin D and analogues
A11C	VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
A11	VITAMINS
A	Alimentary tract and metabolism

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for calcitriol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	CALCITRIOL	calcitriol	CAPSULE;ORAL	204556-002	Feb 21, 2019		DISCN	No	No
Long Grove Pharms	CALCITRIOL	calcitriol	INJECTABLE;INJECTION	078066-002	Jan 29, 2008		DISCN	No	No
Esjay Pharma	ROCALTROL	calcitriol	SOLUTION;ORAL	021068-001	Nov 20, 1998	AA	RX	Yes	Yes
Fresenius Medcl	CALCITRIOL	calcitriol	INJECTABLE;INJECTION	075766-001	Feb 20, 2003		DISCN	No	No

Expired US Patents for calcitriol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-002	Sep 25, 1986	6,051,567*PED
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986	6,265,392*PED
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-001	Approved Prior to Jan 1, 1982	3,697,559
Abbvie	CALCIJEX	calcitriol	INJECTABLE;INJECTION	018874-001	Sep 25, 1986	4,308,264*PED

Market Dynamics and Financial Trajectory for CALCITRIOL

Last updated: February 13, 2026

Overview and Current Market Position

Calcitriol, a synthetic active form of vitamin D3, is primarily prescribed for conditions related to calcium and phosphate imbalance, notably secondary hyperparathyroidism in chronic kidney disease (CKD) and certain forms of osteoporosis. The drug has regulatory approval in multiple markets, including the U.S., Europe, and Asia.

Worldwide, the calcitriol market has experienced steady growth driven by increasing CKD prevalence, aging populations, and expanding indications. The global vitamin D analogs market, of which calcitriol constitutes a significant segment, was valued at approximately USD 1.4 billion in 2022. Experts project a compound annual growth rate (CAGR) of about 4% through 2028.

Market Drivers and Challenges

Drivers:

• Rising incidence of CKD, especially in developing nations.
• Aging demographics increasing prevalence of osteoporosis.
• Widening indications for calcium regulation therapies.
• Growing awareness of vitamin D's role in health.

Challenges:

• Competition from other vitamin D analogs, including paricalcitol and doxercalciferol.
• Patent expirations leading to increased generic penetration.
• Pricing pressures from healthcare systems.
• Development of new treatments for CKD-related bone-mineral disorders that may replace calcitriol.

Regulatory Landscape and Patent Status

Calcitriol was first approved in the 1980s. Several formulations are off-patent, with generic versions dominating the market. Nestlé, Teva, Mylan, and several regional manufacturers sell generic calcitriol. Patent protections for some formulations have expired, prompting price competition and affecting profit margins.

Emerging formulations or delivery methods, such as sustained-release or combination therapies, may offer proprietary advantages and extend market exclusivity in specific regions.

Pricing Trends and Reimbursement Policies

Generic availability has driven down prices. Prices per 0.25 mcg capsule range broadly by region, averaging USD 0.10 to USD 0.30. Reimbursement policies favor cost-effective generic options, influencing sales volumes and profit margins for producers.

In the U.S., Medicare and Medicaid largely cover calcitriol, which supports widespread access. However, pricing pressure remains high due to formulary negotiations and competitive bidding.

Market Growth and Revenue Forecasts

Analysts project that the calcitriol market will attain a CAGR of 3.5-4% over the next five years, reaching approximately USD 1.8 billion globally by 2028. Growth is driven mainly by developing nations' increasing healthcare infrastructure, CKD burden, and osteoporosis management.

Pricing constraints, patent expirations, and proliferation of generics are expected to moderate revenue growth. The market may see increased revenues from emerging indications or novel formulations, though these are not yet widespread.

Competitive Dynamics

Key players include:

• Renowned manufacturers with longstanding market presence: Roche (predecessor of some formulations),AbbVie, and generic companies.
• New entrants focusing on niche formulations or combination drugs.
• Existence of several generic manufacturers competing primarily on price.

Market share is fragmented due to regional licensing and manufacturing differences, but no single entity dominates global sales.

Implications for Investors and R&D

The opportunity for profit lies in developing differentiated formulations or combination therapies, which can command higher prices or extended market exclusivity. Companies should evaluate patent landscapes and regional regulatory pathways meticulously.

Investing in emerging markets presents growth opportunities, especially where healthcare infrastructure development increases CKD treatment access. However, investments must account for market saturation, regulation, and pricing pressures.

Conclusion

Calcitriol maintains a steady, mature presence in the vitamin D analog segment, with growth primarily influenced by global CKD and osteoporosis trends. Patent expirations and generic competition substantially affect pricing and revenue trajectories. Future profitability hinges on innovation, regional market expansion, and pricing strategies amid regulatory environments.

---

Key Takeaways

• Global calcitriol market is valued at USD 1.4 billion (2022), with a 4% CAGR forecast through 2028.
• Market growth driven by CKD and osteoporosis prevalence, especially in aging and developing populations.
• Significant price erosion due to patent expirations and widespread generic competition.
• Revenue prospects are more stable with proprietary formulations or combination drugs.
• Emerging markets offer new growth opportunities but require navigating regional regulatory and reimbursement policies.

---

FAQs

1. How saturated is the calcitriol market?
Market saturation is high due to widespread patent expirations and dominance of generics, limiting profit margins for new entrants.

2. What regions are expanding fastest for calcitriol?
Developing nations in Asia and Latin America are experiencing faster growth owing to increasing CKD and osteoporosis awareness.

3. What are the primary regulatory hurdles for new calcitriol formulations?
Regulatory approval depends on demonstrating bioequivalence for generics or safety and efficacy for novel formulations. Different regions have varying standards.

4. Can calcitriol capture new therapeutic indications?
Potential exists for expansion into immune modulation or cancer-related therapies, but clinical evidence and regulatory approval are needed.

5. How does the competitive landscape influence pricing?
Price competition among generic manufacturers results in standardized, low-cost pricing, pressuring profit margins but expanding access.

---

Citations
[1] Research and Markets, “Vitamin D Analogs Market Forecasts,” 2023.
[2] Evaluate Pharma, “Global Calcitriol Market Trends,” 2022.
[3] GlobalData, “CKD and Osteoporosis Market Analysis,” 2023.